Chemical industry in United States

projects tracked
253
active
129
chemical parks
21

Projects in United States

chemXplore tracks 253 projects in United States, of which 129 are active.

  1. 46 projects Announced / Concept
  2. 13 projects FEED / Pre-FID
  3. 10 projects FID / Sanctioned
  4. 47 projects Under Construction
  5. 13 projects Commissioning & Start-up

Of the active ones, 88 new construction, 34 expansion, 4 revamp / retrofit and 3 conversion / repurposing.

Expected start-up, by year
0 5 10 15 2026 2027 2028 2029 2030 2031

56 active projects carry no start-up date yet. The dates themselves, per project, are for subscribers.

What moved recently

  • 2 October 2026 Bayer New Albany pharmaceutical manufacturing campus · Announced / Concept
  • October 2026 NXTClean Fuels Port Westward renewable diesel and SAF plant · On Hold / Postponed
  • 1 October 2026 Nouryon Morris on-site solar installation · Operational / Completed
  • 29 September 2026 Mesabi Metallics Iowa steel complex · Announced / Concept
  • 28 September 2026 Ultium Cells Spring Hill LMR prismatic cell upgrade · Announced / Concept

Latest American chemical industry news

13 October 2026
Asahi Kasei Therapeutics' HOVILPRI approved for refractory mucocutaneous HSV in immunocompromised adults

Oral helicase‑primase inhibitor pritelivir is the first novel‑mechanism FDA‑approved HSV therapy in ~30 years; Phase 3 showed 63% vs 34% healing by Day 28. US availability expected before end of 2026.

12 October 2026
Trafigura agrees 10-year offtake for 100,000 t of battery-grade lithium from EnergyX

Covers carbonate from Antofagasta and hydroxide from Texas; Trafigura takes 66% of Black Giant Phase 1 and 30% of Lonestar Phase 1, aiding US supply chain and project financing.

10 October 2026
Genentech: One-year Phase III data for vamikibart in uveitic macular edema

Vamikibart showed sustained vision gains and reduced macular thickness at 52 weeks in MEERKAT and SANDCAT; FDA has accepted the BLA with a decision due by July 2027.

10 October 2026
Merck: BRUNELLO one-year data — remigromig non-inferior to ranibizumab in DME

Remigromig met non-inferiority for mean BCVA change versus monthly ranibizumab at one year in DME; higher rates of PDR-related adverse events and discontinuations were reported.

9 October 2026
Arkema showcases battery material solutions at US Battery Show 2026

Highlights binders, PVDF and thermal/safety materials for EV and stationary batteries; 15% PVDF capacity expansion completed in June 2026; visit Booth #2714 Oct 12–15 in Detroit.

9 October 2026
Eli Lilly: Taltz plus Zepbound show broader immunometabolic biomarker changes in TOGETHER‑PsO

Combination therapy produced broader psoriasis-related and metabolic biomarker changes vs Taltz alone as early as Week 12, with greater reductions in inflammatory and neutrophil markers.

9 October 2026
Johnson & Johnson ICOTYDE delivers durable 2‑year plaque psoriasis results

Phase 3 data show sustained PASI90/PASI100 and IGA 0/1 responses to Week 112, durable itch improvement, and no new safety signals.

8 October 2026
Genentech: FDA approves Tecentriq plus fluoropyrimidine and oxaliplatin as adjuvant for stage III dMMR colon cancer

FDA backs first adjuvant immunotherapy regimen for stage III dMMR colon cancer after ATOMIC showed a 50% reduction in recurrence or death with Tecentriq added to chemotherapy.

8 October 2026
BASF launches GLYTHERMIN® coolants for liquid‑cooled data centers

Propylene‑glycol heat‑transfer fluids for direct liquid cooling; DC PG25 is NVIDIA DSX Ready Coolant; BASF cites backward integration for supply reliability and corrosion protection tech.

8 October 2026
Bayer’s finerenone sNDA accepted by FDA for CKD without diabetes

FDA acceptance of finerenone sNDA for adults with CKD without diabetes follows Phase III FIND‑CKD showing slower eGFR decline and reduced cardio‑kidney events versus placebo.

Chemical parks and clusters

active / all projects

The 10 with the most active projects, of 21 parks.